MX2018007637A - Formulacion inyectable de una lactona macrociclica y levamisol. - Google Patents

Formulacion inyectable de una lactona macrociclica y levamisol.

Info

Publication number
MX2018007637A
MX2018007637A MX2018007637A MX2018007637A MX2018007637A MX 2018007637 A MX2018007637 A MX 2018007637A MX 2018007637 A MX2018007637 A MX 2018007637A MX 2018007637 A MX2018007637 A MX 2018007637A MX 2018007637 A MX2018007637 A MX 2018007637A
Authority
MX
Mexico
Prior art keywords
levamisole
macrocyclic lactone
injectable formulation
triacetin
formulations
Prior art date
Application number
MX2018007637A
Other languages
English (en)
Inventor
Fernando Vettorato Luis
Rafael Santos ASSIS Ulisses
Daniel CORTEZ Luiz
Original Assignee
Intervet Int Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Intervet Int Bv filed Critical Intervet Int Bv
Publication of MX2018007637A publication Critical patent/MX2018007637A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/429—Thiazoles condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/10—Anthelmintics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dispersion Chemistry (AREA)
  • Dermatology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La presente invención se refiere a formulaciones para controlar parásitos, que comprende una combinación de un compuesto de lactona macrocíclica y levamisol, en donde el levamisol está en forma particulada suspendida en triacetina y tiene un tamaño de partícula efectivo promedio (D50) de = 250 µm.
MX2018007637A 2015-12-22 2016-12-21 Formulacion inyectable de una lactona macrociclica y levamisol. MX2018007637A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562270721P 2015-12-22 2015-12-22
PCT/EP2016/082188 WO2017108954A1 (en) 2015-12-22 2016-12-21 Injectable formulation of a macrocyclic lactone and levamisole

Publications (1)

Publication Number Publication Date
MX2018007637A true MX2018007637A (es) 2018-09-21

Family

ID=57629585

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2018007637A MX2018007637A (es) 2015-12-22 2016-12-21 Formulacion inyectable de una lactona macrociclica y levamisol.

Country Status (6)

Country Link
EP (1) EP3393455B1 (es)
AR (1) AR107108A1 (es)
AU (2) AU2016377165B2 (es)
BR (1) BR112018012886B1 (es)
MX (1) MX2018007637A (es)
WO (1) WO2017108954A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA127456C2 (uk) * 2017-11-07 2023-08-30 Інтервет Інтернешнл Б.В. Ін'єкційна ізоксазолінова фармацевтична композиція та її застосування

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1375291A (zh) * 2001-03-16 2002-10-23 王玉万 一种含左旋咪唑或其盐类的兽用复方注射剂
NZ552040A (en) * 2006-12-13 2009-04-30 Bomac Research Ltd Veterinary formulation comprising an anthelmintic compound and glyceryl acetate
NZ594610A (en) * 2011-08-16 2013-03-28 Virbac New Zealand Ltd Injectable Anthelmintic Formulations cotaining levamisole and one or more macrocyclic lactones for controlling internal parasites in ruminants
WO2013043064A1 (en) * 2011-09-23 2013-03-28 Alleva Animal Health Limited Veterinary anthelmintic delivery system
CN104983680A (zh) * 2015-06-25 2015-10-21 中国科学院东北地理与农业生态研究所 一种羊用复方驱虫药的稳定性纳米悬浮制剂及其制备方法

Also Published As

Publication number Publication date
AU2016377165B2 (en) 2022-08-11
AU2022268378A1 (en) 2022-12-15
EP3393455A1 (en) 2018-10-31
WO2017108954A1 (en) 2017-06-29
AU2016377165A1 (en) 2018-06-14
BR112018012886A2 (pt) 2018-12-04
EP3393455B1 (en) 2021-07-21
BR112018012886B1 (pt) 2024-02-15
AR107108A1 (es) 2018-03-21

Similar Documents

Publication Publication Date Title
EP3458074A4 (en) COMPOSITIONS FOR DISPENSING TRNA NANOPARTICLES AND METHOD FOR USE THEREOF
MX2021011906A (es) Composiciones de liberacion retardada de linaclotida.
UA117685C2 (uk) Складена композиція для перорального введення, яка містить езетиміб та розувастатин
EP3159338A4 (en) Pyrimidine-2,4-diamine derivative and anticancer pharmaceutical composition comprising same as effective ingredient
EP3535252A4 (en) COMPOSITION COMPRISING A COMBINATION OF EPICATECHIN AND ANTI-CANCER COMPOUND
PL3065732T3 (pl) Związki, kompozycje i odpowiednie zastosowania do zapobiegania i/lub leczenia dyslipidemii
WO2014144295A8 (en) Ceftolozane antibiotic compositions
EP3074000A4 (en) Suspension compositions of physiologically active phenolic compounds&methods of making and using the same
PH12017502376A1 (en) Oral solid formulation containing irinotecan and method of preparing the same
EP3103453A4 (en) Medicinal composition comprising diamino heterocyclic carboxamide compound as active ingredient
AU2015316010A8 (en) Crystalline forms of 6-( (6, 7-dimethoxyquinazolin-4-yl) oxy) -N,2-dimethylbenzofuran-3-carboxamide
EP3357515A4 (en) COMPOSITION FOR SOLID PREPARATION EASY TO USE, EASY SOLID PREPARATION FOR USE COMPRISING SAID PARTICLE COMPOSITION
PH12016500855A1 (en) Pharmaceutical preparation and method of its production and use
IL243737B (en) History of -2amino-4-[3-(-7 fluoro-2-oxo-isoquinolin-1-yl)phenyl]-6-azoloamino-5,3,1-triazine and pharmaceutical preparations containing them
EP3520614A4 (en) FIGHTING NEMATODES WITH GRAMMICIN COMPOUND AS AN ACTIVE SUBSTANCE AND USE THEREOF
MX2017008983A (es) Composición farmaceútica de sulfonamida.
EP3292872A4 (en) COMPOSITION FOR TREATING OR PREVENTING INFLAMMATORY INFECTIOUS DISEASES OR COMPOSITION FOR ENHANCING IMMUNITY COMPRISING TRYPTOPHANYL-ARNT SYNTHASE AS ACTIVE INGREDIENT
HK1248225A1 (zh) 二氫吡嗪並吡嗪化合物的藥物組合物、其固體形式和它們的用途
MX336924B (es) Formulacion inyectable de una lactona macrociclica y levamisol.
EP3400214A4 (en) COMPOSITIONS OF 7-AZONIABICYCLO [2.2.1] HEPTANE DERIVATIVES FOR DRY POWDER INHALATORS
MX2018007637A (es) Formulacion inyectable de una lactona macrociclica y levamisol.
EP3490530A4 (en) SLOW RELEASE COMPOSITION OF ACTIVE INGREDIENTS
IN2013MU01177A (es)
EP3006434A4 (en) Novel compound derived from plant of genus quamoclit and composition containing same as active ingredient for preventing or treating diabetes
WO2016071405A3 (en) Pharmaceutical preparation and method of its production and use